- Report
- December 2025
- 150 Pages
Global
From €5324EUR$5,950USD£4,553GBP
- Report
- January 2026
- 182 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 181 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 196 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 196 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 190 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 194 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 184 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 181 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- August 2026
- 183 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- January 2026
- 195 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- January 2026
- 197 Pages
Global
From €3172EUR$3,545USD£2,713GBP
€3524EUR$3,939USD£3,014GBP
- Report
- May 2026
- 193 Pages
Global
From €4026EUR$4,500USD£3,443GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- February 2026
- 250 Pages
Global
From €4017EUR$4,490USD£3,436GBP
- Report
- August 2026
- 459 Pages
Global
From €5234EUR$5,850USD£4,476GBP
- Report
- August 2026
- 582 Pages
Global
From €5234EUR$5,850USD£4,476GBP
- Report
- August 2026
- 270 Pages
Global
From €5234EUR$5,850USD£4,476GBP

The Soft Mist Inhaler (SMI) is a type of inhaler used to deliver medication to the lungs. It is a breath-activated device that produces a fine mist of medication, which is then inhaled by the patient. SMIs are used to treat a variety of respiratory conditions, including asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis. They are also used to deliver medications for other conditions, such as allergies and COPD.
SMIs are becoming increasingly popular due to their convenience and ease of use. They are also more cost-effective than other inhalers and nebulisers, making them a viable option for many patients. SMIs are also more discreet than other inhalers, making them a preferred choice for those who need to take their medication in public.
The SMI market is highly competitive, with a number of companies offering a range of products. These include GlaxoSmithKline, Boehringer Ingelheim, Novartis, Merck, and AstraZeneca. Other companies in the market include 3M, Philips, and Teva Pharmaceuticals. Show Less Read more